PBYI Puma Biotechnology Inc

+0.88  (+4%)
Previous Close 23.68
Open 23.92
Price To Book 20.47
Market Cap 936595453
Shares 38,134,994
Volume 668,893
Short Ratio
Av. Daily Volume 1,220,301

SEC filingsSee all SEC filings

  1. 8-K - Current report 19527155
  2. 8-K - Current report 181239259
  3. 8-K - Current report 181233195
  4. 8-K - Current report 181191249
  5. 8-K - Current report 181171188

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released at ASCO June 3, 2017.
HER2-positive metastatic breast cancer patients with brain metastases
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 data released December 6, 2018 noted ORR 30%; 9% CR.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data December 6, 2018. Noted grade 3 diarrhea occurred in 40% of patients compared with 2% for placebo.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 3 data released December 17, 2018. PFS endpoint met but OS co-primary missed.
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Approval announced July 17, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
Neratinib (NERLYNX)
Extended adjuvant HER2-positive early stage breast cancer
Phase 1/2 interim data presented at ASCO June 2018. 9 PRs, 3CRs out of 20 patients.
Neratinib plus Kadcyla (T-DM1)
HER2-positive metastatic breast cancer

Latest News

  1. Is Puma Biotechnology a Buy?
  2. See what the IHS Markit Score report has to say about Puma Biotechnology Inc.
  3. Detailed Research: Economic Perspectives on Delta Air Lines, Duke Energy, Fiserv, The Chefs' Warehouse, Maxim Integrated Products, and Puma Biotechnology — What Drives Growth in Today's Competitive Landscape
  4. Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
  5. Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
  6. Knight Therapeutics Runs with Exclusive Canadian License to Puma’s NERLYNX®
  7. Athenex Completes Enrollment Target for Breast Cancer Study
  8. Puma Biotechnology to Present at J. P. Morgan Healthcare Conference
  9. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  10. A Bull And Bear Review Positive Results For Puma Biotech's Late-Stage Breast Cancer Drug Trial
  11. Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer
  12. The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan
  13. Today's Research Reports on Trending Tickers: Puma Biotechnology and FibroGen
  14. Puma Bio stock rises more than 9% on drug study
  15. Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
  16. Puma Biotechnology Inc (PBYI): Hedge Fund Sentiment Unchanged
  17. 3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
  18. Investor Expectations to Drive Momentum within CatchMark Timber Trust, Edison International, Puma Biotechnology, Maxim Integrated Products, Wabash National, and Resolute Energy — Discovering Underlying Factors of Influence

SEC Filings

  1. 8-K - Current report 19527155
  2. 8-K - Current report 181239259
  3. 8-K - Current report 181233195
  4. 8-K - Current report 181191249
  5. 8-K - Current report 181171188
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181158932
  7. 8-K - Current report 181153631
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181115537
  9. CT ORDER - Confidential treatment order 181040421
  10. 8-K - Current report 181005129